Know What's Happening in Industry

J&J Reports Long-Term QUASAR Data for Tremfya in Ulcerative Colitis

Johnson & Johnson released long‑term QUASAR extension data for Tremfya (guselkumab) in ulcerative colitis, showing sustained efficacy through week 140. Clinical remission was achieved by 80.8% of patients, with 78.6% attaining histo‑endoscopic improvement and 53.6% reaching endoscopic remission. Approximately 89% of eligible participants completed the 140‑week regimen, and remission rates were consistent regardless of prior biologic or JAK inhibitor exposure. No new safety signals emerged, and most patients in remission were corticosteroid‑free for at least eight weeks.